Table 1.
Incidence of respiratory events in various types of immunocompromised patients
| Incidence of respiratory events | Need for ICU admission | Hospital respiratory mortality | |
|---|---|---|---|
| Haematological malignancies | |||
| Acute myeloid leukaemia5, 18, 19, 20, 21, 22, 23 | 22–84% | 66% | 45% |
| Acute lymphoblastic leukaemia18, 22, 23 | 7–18·5% | 12–15% | 38·5% |
| Lymphoproliferative diseases5 | 8% | 8% | 40-50% |
| Myelodysplastic syndrome18 | 29·4% | 20% | 17% |
| Autologous haemopoietic stem cell therapy24, 25 | 3–28% | 42% | 3–55% |
| Allogeneic haemopoietic stem cell therapy26, 27 | 24–30% | 50% | 51% |
| Prolonged neutropenia6, 28 | 8–29·5% | 11–16% | 5–12% |
| Solid tumours | |||
| Lung cancer29, 30 | 26–50% | 100% | 11·2–60% |
| Other solid tumours5, 30, 31 | 0·7–10·3% | 100% | 6·1–55% |
| Patients on immunotherapy32, 33 | 1·3–3·6% | 1·3%* | .. |
| Solid organ transplantation | |||
| Lung transplantation34 | 14% | All | 65% |
| Heart transplantation35 | 12·5% | All | 76·5% |
| Kidney transplantation36, 37 | 3·3–4·8% | All | 16·4–22·5% |
Data on patients with drug-related immunosuppression are sparse.
*
Refers to grade 3–4 toxicities. ICU=intensive care unit.